Roche’s Q3 sales soar, and also secures new partnership with Warm Drive Bio
With recent news that Roche’s third quarter sales have risen by 6%, the company is continuing its dominance within the pharmaceutical market. Its new drug to treat chronic condition multiple sclerosis is one of many factors surrounding its positive results.
Gaining over 13 billion Swiss Francs, in comparison to 12.48 billion a year earlier, Roche’s other medicines, such as Perjeta and Alecensa have also supported business growth.
"Based on the strong sales growth of our pharmaceuticals and diagnostics divisions in the first nine months, I am confident that we will achieve our full-year targets. The growth is largely driven by new product launches. I am particularly pleased about the regulatory approvals of Tecentriq, Gazyvaro and RoActemra in the EU," commented Chief Executive Severin Schwan.
Sales have rose internationally, with strong sales growth in both the US and Japan especially.
- Healthcare sector the worst offender in race towards General Data Protection Regulation compliance
- The use of AI will transform patient outcomes, report finds
- NowRx aims to disrupt the pharmacy market
The company’s new partnership with Warp Drive Bio will also raise Roche’s profile significantly, as it aims to further support the development of new antibiotics. Through the deal, Warp Drive will implement its Genome Mining Platform, and will further analyse natural product medicines which have not been looked at in depth previously to further this development.
Roche will consequently look to ultimately distribute any new antibiotic drug on the commercial market, although Warp Drive Bio will retain all rights surrounding any developments.
“Antimicrobial resistance is an extraordinary threat to global human health, and Warp Drive’s unique platform allows us to access a vast reservoir of uncharacterised natural products from which to identify novel antibiotics,” commented Laurence Reid, Warp Drive Bio’s Chief Executive.
NHS trials test that predicts sepsis 3 days in advance
A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England.
Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year.
The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time.
From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.
Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction.
Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.
The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years.
If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.
Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”